Clinical trials: Early Breast Cancer, open to volunteers
Breast Cancer Early Stage Breast Cancer (Stage 1-3), HER2
A Composite Assay for HER2-positive Early-stage Breast Cancer Management
The goal of this observational study is to assess the prognostic value of a genomic classifier (S18) and its refined version (S*) in women with early-stage HER2-positive breast cancer.
- Trial name
- HERCard (NCT06762977)
- Where
- 2 sites in Italy
- Volunteers
- 180 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Carcinoma
PARTial BREast RECONstruction With Chest Wall Perforator Flap
The goal of this observational study is to ascertain the outcomes following partial breast reconstruction using chest wall perforator flaps after breast conservation surgery.
- Conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Carcinoma, Breast Neoplasms, Breast Surgery
- Trial name
- PartBreCon (NCT06728527)
- Where
- United Kingdom
- Volunteers
- 1,001 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
"The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients"
Cancer is currently a leading cause of morbidity and mortality worldwide. Chemotherapeutic agents, despite being effective in arresting the progression of cancer by targeting and eliminating rapidly dividing cancer cells, are…
- Trial name
- NCT06679387
- Testing
- Memantine-HCl
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Outcomes of a Novel Technique Minimal Scar Mastectomy
Nipple sparing mastectomy is oncologically safe and has a good cosmetic outcome. However, nipple sparing mastectomy was conventionally performed with reconstruction.
- Trial name
- NCT06676761
- Testing
- nipple sparing mastectomy without reconstruction
- Where
- 2 sites in Singapore
- Volunteers
- 100 people
- Sponsor
- KK Women's and Children's Hospital
Breast Cancer Early Stage Breast Cancer (Stage 1-3), SBRT
A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial
Radiotherapy (RT) is a fundamental pillar in the fight against cancer. In the case of breast cancer, RT has traditionally been applied as an adjuvant treatment following surgery.
- Trial name
- DESERT-I (NCT06671691)
- Testing
- SBRT level I, SBRT level II, SBRT level III
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Universitat de les Illes Balears
Breast Cancer Nos Metastatic Recurrent, Early Lung Cancer
Chronic Toxicities Related to Treatment in Patients With Localized Cancer
The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic cancer.
- Trial name
- CANTO (NCT01993498)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 14,750 people
- Sponsor
- UNICANCER
Early Breast Cancer, Metabolic Health
Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy
This clinical trial aims to investigate early metabolic health changes in early breast cancer patients that initiate antihormone therapy.
- Conditions
- Early Breast Cancer, Metabolic Health, Estrogen Receptor Positive Breast Cancer
- Trial name
- EMETA (NCT06623903)
- Where
- Denmark
- Volunteers
- 112 people
- Sponsor
- Aarhus University Hospital
Early Breast Cancer
Aromatherapy in the Treatment of Early Breast Cancer
Breast cancer is a major threat to women's health, and chemotherapy is one of the most important treatment method. Chemotherapy is cytotoxic , and has a positive tumor immune effect.
- Trial name
- NCT06435104
- Testing
- neoadjuvant chemotherapy, aromatherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early Breast Cancer, Neoadjuvant Therapy
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel followed by AC/EC in a neoadjuvant setting, in high-risk, ER+/HER2- early breast cancer.
- Conditions
- Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer
- Trial name
- QUEEN-Neo (NCT06404463)
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Albumin-bound paclitaxel, Doxorubicin
- Volunteers
- 76 people
- Sponsor
- Fudan University
Early Breast Cancer, Neoadjuvant Therapy
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel and carboplatin in a neoadjuvant setting, in high-risk, TNBC early breast cancer.
- Conditions
- Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
- Trial name
- QUEEN-Dream (NCT06404736)
- Testing
- Bispecific antibody (bsAb) targeting PD-1 and CLTA-4, Albumin-bound paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Fudan University
Early Breast Cancer, Triple Negative Breast Cancer
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
Phase II, randomized, Active-controlled open label trial for treatment of high risk, HR-/HER2- (triple negative) breast cancer, with two sequences of neoadjuvant chemotherapy on a background of pembrolizumab
- Trial name
- KEYPARTNER (NCT06371807)
- Testing
- Pembrolizumab injection
- Where
- 3 sites in Portugal
- Volunteers
- 20 people
- Sponsor
- Fundacao Champalimaud
Early-stage Breast Cancer, Breast Carcinoma in Situ
Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
This is a prospective, registry study that will enroll all women with early stage breast cancer who will be treated with intraoperative radiotherapy (IORT) during breast-conserving surgery.
- Conditions
- Early-stage Breast Cancer, Breast Carcinoma in Situ, Breast Neoplasms
- Trial name
- NCT04603209
- Testing
- Intraoperative Radiation Therapy (IORT)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Saint John's Cancer Institute
Early Breast Cancer
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
The investigator conduct a phase II multi-center, open-label trial to evaluate efficacy and safety of dalpiciclib with endocrine therapy as adjuvant treatment in patients with medium /high risk hormone receptor-positive…
- Trial name
- NCT06341894
- Testing
- Dalpiciclib, Endocrine therapy
- Where
- China
- Volunteers
- 1,163 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
HER2-positive Breast Cancer, Early-stage Breast Cancer
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
This is a prospective, multicenter, registry-based cohort study to explore the efficacy and safety of Pyrotinib combined with Capecitabine for adjuvant treatment of HER2 positive early breast cancer compared with treatment of…
- Trial name
- NCT06035016
- Testing
- pyrotinib combined with Capecitabine, treatment of physician's choice
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
HER2 Positive Early Breast Cancer
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
compare the efficacy and safety of TCbHP and EC-THP regimen in HER2-positive breast cancer patients
- Trial name
- NCT05883852
- Testing
- Docetaxel, carboplatin, Trastuzumab
- Where
- China
- Volunteers
- 1,406 people
- Sponsor
- Fudan University
Early-stage Breast Cancer
Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer
This study is a prospective, multi-center, open-label cohort study, with 3 years disease free survival(DFS) as the primary endpoint.
- Trial name
- AMENDER (NCT05345860)
- Testing
- The MRD strategy for high risk or MRD+ TNBC patients, The MRD strategy for high risk or MRD+ HER2+ patients, The MRD strategy for high risk or MRD+ ER+ patients
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
HER2-negative Early Breast Cancer
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients
Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients with triple negative subtype who achieved pCR after neoadjuvant treatment would have longer survival.
- Trial name
- NCT04836156
- Testing
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer, neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University People's Hospital
HER2-positive Early Breast Cancer
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients with her2 enriched subtype who achieved pCR after neoadjuvant treatment would have longer survival.
- Trial name
- NCT04750122
- Testing
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University People's Hospital
Early Breast Cancer, Radiation Associated Cardiac Failure
The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer
The majority of early breast cancer patients are treated with adjuvant radiation therapy (RT) as part of their multimodal therapy.
- Trial name
- NCT04291378
- Testing
- Proton versus photon radiation therapy
- Where
- 8 sites in Denmark
- Volunteers
- 1,502 people
- Sponsor
- Danish Breast Cancer Cooperative Group
Early Hormone Receptor-positive Breast Cancer
Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy
A prospective, randomized, comparative study to evaluate efficacy of anticancer chemotherapy in predicting prognosis and determining chemotherapy method in early Hormone Receptor-positive breast cancer patients with…
- Trial name
- NCT04278469
- Testing
- Chemotherapy Drugs, Cancer
- Where
- South Korea
- Volunteers
- 194 people
- Sponsor
- Gencurix, Inc.